口服服BX795的耐受性,药理动力学和抗疹活性
Tejabhiram Yadavalli1, Sudhanshu Kumar Singh2, Abhijit A Date3
1Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.
概括
BX795,一种抗病毒药物,在简单疹病毒 (HSV) 感染时口服时耐受性良好且有效. 口服可显著减少眼睛和生殖器组织中的病毒复制.
科学领域:
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
背景情况:
- 简单疹病毒 (HSV-1和HSV-2) 导致显著的眼睛,耳鼻面部和生殖器疾病.
- 新兴的抗核类药物耐药性需要新的抗病毒药物.
- BX795,一种局部抑制剂,已经显示出希望,但其全身疗效需要研究.
研究的目的:
- 评估口服BX795.5的毒性,药理动力学和组织分布.
- 在小鼠模型中评估口服BX795对眼部HSV-1和生殖器HSV-2感染的体内抗病毒疗效.
主要方法:
- 在小鼠中进行口服BX795 (400和100毫克/公斤) 的急性和短期毒性研究.
- 静脉内和口服后的药理动力学和组织分布分析.
- 在眼睛和生殖器疹感染的小鼠模型中的体内抗病毒疗效评估.
主要成果:
- 口服的BX795在小鼠中耐受良好.
- BX795的口服生物利用率为56%.
- 药物在口服后15分钟内迅速分布到眼睛和生殖器组织.
- 口服BX795显著减少了眼睛和生殖器组织中的疹病毒复制.
结论:
- 口服BX795在治疗HSV感染方面是安全有效的.
- BX795具有有利的药理动力学特性,包括良好的口服生物可用性和快速组织分布.
- 对BX795的全身管理代表了对眼睛和生殖器疹的有前途的治疗策略.
相关概念视频
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
231
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
231
Biopharmaceutics and Pharmacokinetics: Overview
2.1K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.1K
Factors Influencing Drug Absorption: Presystemic Elimination
265
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
265
Hepatic Drug Clearance: Role of Transporters
87
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
87
Factors Influencing Drug Absorption: Drug Dissolution
587
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
587
Drug Biotransformation: Overview
2.5K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.5K


